RNS Notification

Source: RNS
RNS Number : 2135U
Dukinfield Plc
27 July 2020
 

RNS Notification

Dukinfield PLC (the "Issuer") 

NOTICE

to the holders of the following notes and certificates

 of the Issuer presently outstanding

£326,000,000 Class A Notes due 2045 (ISIN: XS1277627086, Common Code: 127762708)

£37,900,000 Class B Notes due 2045 (ISIN: XS1277634371, Common Code: 127763437)

£33,300,000 Class C Notes due 2045 (ISIN: XS1277636400, Common Code: 127763640)

£16,100,000 Class D Notes due 2045 (ISIN: XS1277637390, Common Code: 127763739)

£25,300,000 Class E Notes due 2045 (ISIN: XS1277638018, Common Code: 127763801)

    £20,700,000 Class F Notes due 2045 (ISIN: XS1277638950, Common Code: 127763895)

(the "Noteholders" and the "Notes", respectively)

Class Z Certificates (ISIN: XS1278921728, Common Code: 127892172)

 (the "Certificateholders" and the "Certificates", respectively)

 Exercise of Call Option

 

The Notes are admitted to the official list of the Irish Stock Exchange plc trading as Euronext Dublin and to trading on its regulated market.

 

This announcement contains inside information and is made by the Issuer pursuant to Regulation (EU) No. 596/2014 (the "Market Abuse Regulation") and Regulation (EU) 2016/1055 (the "Implementing Technical Standards") relating thereto.

 

Capitalised terms used, but not defined herein, shall have the meaning given thereto in the Prospectus dated 17 September 2015.

 

NOTICE IS HEREBY GIVEN that the Option Holder has served notice on the Issuer to exercise the Option Holder Call Option and accordingly the Notes shall be redeemed in full by the Issuer on the Interest Payment Date falling on 17 August 2020.

 

This notice is given by:

 

Dukinfield PLC

 

Dated 27 July 2020

 

 

 

 

This announcement has been issued through the Companies Announcement Service of Euronext Dublin.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ISERRMATMTTTBJM